Welcome to our dedicated page for Blueprint Medicines news (Ticker: BPMC), a resource for investors and traders seeking the latest updates and insights on Blueprint Medicines stock.
Blueprint Medicines Corporation (Nasdaq: BPMC) generates frequent news as a global, fully integrated biopharmaceutical company focused on allergy/inflammation and oncology/hematology. Its news flow centers on systemic mastocytosis (SM) and mast cell-driven diseases, where the company is advancing AYVAKIT/AYVAKYT (avapritinib), elenestinib and BLU-808, as well as targeted oncology programs.
On this page, readers can follow BPMC news related to clinical data, regulatory milestones, corporate transactions and financial updates. Recent announcements include long-term efficacy and safety data for AYVAKIT/AYVAKYT in indolent and advanced SM from trials such as PIONEER, PATHFINDER and EXPLORER, as well as real-world studies like PRISM that characterize the burden of SM on patients’ daily lives. News items also cover progress in the HARBOR trial of elenestinib, Phase 1 data for BLU-808 in healthy volunteers, and the launch of multiple proof-of-concept studies in mast cell-mediated allergic and inflammatory diseases.
Investors and healthcare observers will also find Blueprint Medicines news on quarterly and annual financial results, revenue guidance for AYVAKIT/AYVAKYT, and strategic corporate developments. A notable development is Sanofi’s agreement to acquire Blueprint Medicines, adding AYVAKIT/AYVAKYT and the company’s early-stage immunology pipeline to Sanofi’s rare disease and immunology portfolio. Earnings releases highlight AYVAKIT/AYVAKYT net product revenues, guidance updates and commentary on the company’s capital position and investment priorities.
Additional coverage includes participation in major medical and investor conferences, such as the American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress, the European Hematology Association Congress, and healthcare investor conferences. Bookmark this page to access a consolidated feed of BPMC news, from clinical presentations and pipeline milestones to transaction updates and corporate outlooks.
Blueprint Medicines reported strong first quarter 2024 results, generating $92.5 million in AYVAKIT net product revenues and raising full-year revenue guidance to $390-$410 million. The company is on track to submit an IND for BLU-808 in Q2 to strengthen its presence in allergy and inflammation. Blueprint Medicines continues to advance its pipeline, with key developments in mast cell disorders and HR+/HER2- breast cancer. Financially, the company anticipates growth in global product revenues, decreased operating expenses, and a strong cash position.
FAQ
What is the current stock price of Blueprint Medicines (BPMC)?
What is the market cap of Blueprint Medicines (BPMC)?
